News
06-04-2012, 12:41 AM
OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.
More... (http://www.news-medical.net/news/20120604/New-data-from-OncoMede28099s-OMP-59R5-Phase-I-study-on-advanced-solid-tumors.aspx)
More... (http://www.news-medical.net/news/20120604/New-data-from-OncoMede28099s-OMP-59R5-Phase-I-study-on-advanced-solid-tumors.aspx)